1. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.
- Author
-
Wang, Peipei, Li, Tuo, Liu, Zhikai, Jin, Mei, Su, Yan, Zhang, Jingjing, Jing, Hongli, Zhuang, Hongming, and Li, Fang
- Subjects
POSITRON emission tomography ,NEUROBLASTOMA ,COMPUTED tomography ,CHILD patients ,SINGLE-photon emission computed tomography - Abstract
Purpose: Iodine 123 labeled meta-iodobenzylguanidine ([
123 I]MIBG) scan with SPECT/CT imaging is one of the most commonly used imaging modalities in the evaluation of neuroblastoma. [18 F]-meta-fluorobenzylguanidine ([18 F]MFBG) is a novel positron emission tomography (PET) tracer which was reported to have a similar biodistribution to [123 I]MIBG. However, the experience of using [18 F]MFBG PET/CT in the evaluation of patients with neuroblastoma is limited. This preliminary investigation aims to assess the efficacy of [18 F]MFBG PET/CT in the evaluation of neuroblastomas in comparison to [123 I]MIBG scans with SPECT/CT. Materials and methods: In this prospective, single-center study, 40 participants (mean age 6.0 ± 3.7 years) with history of neuroblastoma were enrolled. All children underwent both [123 I]MIBG SPECT/CT and [18 F]MFBG PET/CT studies. The number of lesions and the Curie scores revealed by each imaging method were recorded. Results: Six patients had negative findings on both [123 I]MIBG and [18 F]MFBG studies. Four of the 34 patients (11.8%) were negative on [123 I]MIBG but positive on [18 F]MFBG, while 30 patients were positive on both [123 I]MIBG and [18 F]MFBG studies. In these 34 patients, [18 F]MFBG PET/CT identified 784 lesions while [123 I]MIBG SPECT/CT detected 532 lesions (p < 0.001). The Curie scores obtained from [18 F]MFBG PET/CT (11.32 ± 8.18, range 1-27) were statistically higher (p < 0.001) than those from [123 I]MIBG SPECT/CT (7.74 ± 7.52, range 0-26). 30 of 34 patients (88.2%) with active disease on imaging had higher Curie scores based on the [18 F]MFBG study than on the [123 I]MIBG imaging. Conclusion: [18 F]MFBG PET/CT shows higher lesion detection rate than [123 I]MIBG SPECT/CT in the evaluation of pediatric patients with neuroblastoma. Clinical trial registration: Clinicaltrials.gov: NCT05069220 (Registered: 25 September 2021, retrospectively registered); Institute Review Board of Peking Union Medical College Hospital: ZS-2514 [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF